METHODS: We performed a systematic retrieval of literature published prior to 26 October 2021. Standardized mean difference (SMD) with a 95% confidence interval (CI) was calculated to evaluate pooled effects. Subgroup analysis and meta-regression analysis were conducted to detect sources of heterogeneity. Sensitivity analysis was performed to evaluate the stability of the study. Publication bias was assessed by funnel plots and Egger\'s linear regression test.
RESULTS: Ten eligible studies with 1269 MM patients and 2158 controls were included. The pooled analyses indicated that circulating leptin levels of MM patients were significantly higher than control levels (SMD= 0.87, 95%CI: 0.33 to 1.41), while the circulating adiponectin levels in MM patients were significantly lower than controls with a pooled SMD of -0.49 (95%CI: -0.78 to -0.20). The difference of circulating resistin levels were not significant between MM patients and controls (SMD= -0.08, 95%CI: -0.55 to 0.39). Subgroup analysis and meta-regression analysis found that sample size, age, and sex were possible sources of heterogeneity. Sensitivity analysis demonstrated our pooled results to be stable.
CONCLUSIONS: Decreased circulating adiponectin and increased leptin levels were associated with the occurrence and development of MM. Adiponectin and leptin may be potential biomarkers and therapeutic targets for MM.
方法:我们对2021年10月26日之前发表的文献进行了系统检索。计算具有95%置信区间(CI)的标准化平均差(SMD)以评估合并效应。进行亚组分析和荟萃回归分析以检测异质性来源。进行敏感性分析以评估研究的稳定性。通过漏斗图和Egger线性回归检验评估发表偏倚。
结果:纳入了10项符合条件的研究,包括1269例MM患者和2158例对照。汇总分析表明,MM患者的循环瘦素水平显着高于对照组水平(SMD=0.87,95CI:0.33至1.41),而MM患者的循环脂联素水平显着低于对照组,合并的SMD为-0.49(95CI:-0.78至-0.20)。循环抵抗素水平在MM患者和对照组之间没有显着差异(SMD=-0.08,95CI:-0.55至0.39)。亚组分析和荟萃回归分析发现,样本量,年龄,和性别是异质性的可能来源。敏感性分析表明我们的合并结果是稳定的。
结论:循环脂联素水平降低和瘦素水平升高与MM的发生发展有关。脂联素和瘦素可能是MM的潜在生物标志物和治疗靶标。